布地奈德联合孟鲁司特治疗支气管哮喘的疗效和安全性观察

Clinical Efficacy and Safety of Budesonide united with Montelukast in Patients with Bronchial Asthma

目的:探讨布地奈德联合孟鲁司特治疗支气管哮喘的疗效和安全性。方法:90例患者随机分为治疗组和对照组,各45例。对照组给予吸氧、抗炎、平喘、化痰等常规治疗,治疗组在常规治疗的基础上加用布地奈德和孟鲁司特,分别比较两者患者的疗效和肺功能等指标。结果:治疗组的有效率高达93.33%,高于对照组的68.89%,差异有统计学意义(P<0.05);治疗组的肺功能改善程度和症状缓解时间均优于对照组,两组比较差异有统计学意义(P<0.05)。结论:布地奈德联合孟鲁司特治疗支气管哮喘具有显著的治疗效果和良好的安全性。

objective To investigate the clinical efficacy and safety of budesonide and montelukast in treating patients with bronchial asthma. Method 90 patients were divided into the therapy group and the control group by half. The patients in the control group were given oxygen inhalation,anti-inflammation,relieving asthma,eliminating phlegm and other conventional treatment. the patients in the therapy group were added the usage of budesonide and montelukast on the basis of conventional treatment. The therapeutic effect and pulmonary function were compared between the two groups. Results The effective rate of the treatment group was 93. 33%,which was higher than 68. 89% in the control group,the difference had statistical significance （P〈0. 05）. The improvement of pulmonary function and the degree of symptom remis-sion time of the treatment group were better than the control group,there was significant difference between the two groups（P〈0. 05）. Con-clusion The treatment combined with budesonide and montelukast could significantly improve the clinical efficacy,and has a good safety.